SAN DIEGO –
Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company
developing novel anti-infectives including immunotherapies, today
announced that new data from studies of its lead antifungal rezafungin
will be presented at the 2018 Hot Topics in Infectious Diseases (HTIDE)
Conference to be held in Mestre, Venice from October 25-26, 2018.
Rezafungin is the only once-weekly antifungal product candidate in
development for the treatment and prevention of life-threatening
invasive fungal infections.
A total of three rezafungin abstracts have been accepted for poster
presentations. Two posters will highlight analyses of rezafungin in
special patient populations and by geographic outcomes based on results
from Cidara’s Phase 2 STRIVE trial. The third poster will highlight the in
vivo efficacy of rezafungin in aspergillosis.
Hot Topics in Infectious Diseases (HTIDE) is a bi-annual conference
which convenes more than 400 delegates from all over the world to
discuss topics on novel approaches to diagnosis and treatment of
infectious diseases. Cidara’s HTIDE posters will be on display
throughout the conference and featured in a poster walk discussion
during the lunch session on both days. Details are as follows:
Title: Rezafungin for the Treatment of Candidemia and/or Invasive
Candidiasis: Analysis of the Global, Randomized, Double-Blind,
Placebo-Controlled Phase 2 STRIVE Clinical Trial by Geographic Region of
Author: T. Sandison, et. al.
Title: Analysis of Patients by Baseline Renal Function from the Phase 2
STRIVE Clinical Trial of Rezafungin for the Treatment of Candidemia
and/or Invasive Candidiasis
Author: S. Flanagan, et. al.
Title: Of Mice and Men: Comparison of Rezafungin versus Micafungin Lung
Exposures in Mouse, and Potential Implications for Human ELF and
Author: V. Ong, et. al.
Copies of these presentations will be available on the Cidara website
following the meeting: www.cidara.com.
Rezafungin is a novel antifungal echinocandin being developed as a
once-weekly, high-exposure therapy for the treatment and prevention of
serious invasive fungal infections. Rezafungin has a unique
pharmacokinetic profile with a prolonged half-life and front-loaded
plasma exposure which, in contrast to all other echinocandins, allows
for once-weekly IV therapy. Rezafungin is being studied to address unmet
needs in the treatment of candidemia and invasive candidiasis as well as
for prophylaxis (prevention) of invasive fungal infections, including Candida,
Aspergillus and Pneumocystis in patients undergoing
allogeneic bone marrow transplantation.
About Cidara Therapeutics
Cidara is a clinical-stage biotechnology company focused on developing
new anti-infectives that have the potential to transform the standard of
care and save or improve patients’ lives. The company is currently
advancing its novel echinocandin antifungal, rezafungin acetate, in a
Phase 3 clinical trial in the treatment of candidemia and invasive
candidiasis and plans to initiate a second Phase 3 trial in the
prophylaxis of invasive fungal infections. Rezafungin has improved
pharmacokinetics compared to existing echinocandins and the potential
for expanded utility across patient settings. It is the only once-weekly
product candidate in development for the treatment and prevention of
life-threatening invasive fungal infections. Cidara also is leveraging
its novel Cloudbreak™ platform to develop antibody-drug conjugates for
the treatment of serious viral and Gram-negative bacterial infections.
Cloudbreak is the first immunotherapy discovery platform designed
specifically to create compounds that directly kill pathogens and also
direct a patient’s immune cells to attack and eliminate bacterial,
fungal or viral pathogens. Cidara is headquartered in San Diego,
California. For more information, please visit www.cidara.com.
Statements contained in this press release regarding matters that are
not historical facts are “forward-looking statements” within the meaning
of the Private Securities Litigation Reform Act of 1995. Because such
statements are subject to risks and uncertainties, actual results may
differ materially from those expressed or implied by such
forward-looking statements. Such statements include, but are not limited
to, statements regarding the initiation of rezafungin Phase 3 pivotal
trials, the potential for rezafungin to be a novel treatment and
prophylactic agent against deadly invasive fungal infections, and
rezafungin’s potential for expanded utility across patient settings.
Risks that contribute to the uncertain nature of the forward-looking
statements include: the success and timing of Cidara’s preclinical
studies and clinical trials; regulatory developments in the United
States and foreign countries; changes in Cidara’s plans to develop and
commercialize its product candidates; Cidara’s ability to obtain
additional financing; Cidara’s ability to obtain and maintain
intellectual property protection for its product candidates; and the
loss of key scientific or management personnel. These and other risks
and uncertainties are described more fully in Cidara’s Form 10-Q most
recently filed with the United States Securities and Exchange
Commission. All forward-looking statements contained in this press
release speak only as of the date on which they were made. Cidara
undertakes no obligation to update such statements to reflect events
that occur or circumstances that exist after the date on which they were